Johnson & Johnson Innovation Spotlight 2021
Since its establishment in 2013, Johnson & Johnson Innovation has supported and collaborated with the Asia Pacific ecosystem to curate and cultivate the best early-stage life science, consumer health and technology innovation for patients and consumers across the world.
Inspiring ideas and disruptive innovation can come from anywhere. We all benefit from collaboration, which is why we continue to bring meaningful solutions and flexible approaches to support innovators at any stage by leveraging our global network of resources, scale, reach and expertise to advance health in the region and around the world.
Dan Wang, MD, MPH, MBA
Head of Johnson & Johnson Innovation Asia Pacific
Through our regional hub, based out of Shanghai, we are deeply embedded within and tightly connected to the external early innovation ecosystem around the world, with offices located in Tokyo, Seoul, Singapore and Hong Kong SAR.
We leverage innovative business models and deploy a suite of capabilities to meet the diverse needs of entrepreneurs, scientists, health technology innovators and emerging companies from across the pharmaceutical, medical device and consumer health sectors.
Flexible and customized partnership models allow us to create the right deal to best suit the technology and the innovator with whom we are working, so that together we can have a meaningful impact on human health around the world.
Strategic Therapeutic Areas
Single Point of Entry for Innovation
We're a single-entry point into a sweeping set of super-charged solutions. Early-stage innovation incubation. Creative deal-making. Strategic deployment of venture capital. Johnson & Johnson Innovation's diverse team of science and technology experts in the Asia Pacific region works with entrepreneurs to flex and shape their solutions to bridge scientific gaps and unlock meaningful improvements in human health.
Depending on where an idea is in its life cycle, integrated Johnson & Johnsons Innovation teams make it easy for our collaborators and partners to tap into our broad and unique range of tools and capabilities, including:
JLABS @ Shanghai: Life Science Incubator
Opened in 2019 to accommodate more than 50 life sciences and healthcare start-ups, JLABS @ Shanghai is more than just the combinations of shared and private lab and office spaces, equipment, value-added solutions, operational support, education and business services - it provides access to an ecosystem that could help transform ideas from concept to reality.
JJDC: Funding and Equity Investment
JJDC is the strategic venture capital arm of Johnson & Johnson with a 49-year legacy. Our experienced investors work to identify transformational ideas in the external ecosystem - from start-up to Series B and beyond - and through investment and advice, help companies to realize their ideas into solutions for patients.
The Lung Cancer Initiative at Johnson & Johnson in China (LCI China)
Established in 2018, LCI China is an integral part of Lung Cancer Initiative at Johnson & Johnson and is made up of a dedicated team focused on the prevention, interception and cure of lung cancer. With expertise across clinical, pharmaceutical, engineering, surgical and early detection sciences, the local team works in strong collaboration with Johnson & Johnson sector partners to advance critical programs.
World Without Disease Accelerator (WWDA)
The WWDA is focused on the discovery, development and delivery of disruptive products/technologies, business models and partnerships to advance the elimination of disease around the world. Working in conjunction with the LCI China team, the WWDA is comprised of entrepreneurial capability teams working to advance disease interception in targeted disease areas, with lung cancer as a key priority.
At Johnson & Johnson Innovation Asia Pacific, we take a tailored approach to different markets in the region based on the strengths of the innovation ecosystems. Below are some examples of successful partnerships we have made in life science hot spots in the region.